补肾调肝方对非肥胖型多囊卵巢综合征患者糖脂代谢的影响

Effects of Bushen Tiaogan Recipe on Glucolipid Metabolism in Non-obese Patients with Polycystic Ovary Syndrome

目的观察补肾调肝方对非肥胖型多囊卵巢综合征(polycystic ovary syndrome,PCOS)糖脂代谢的影响。方法将60例肾虚肝郁型非肥胖型PCOS(BMI<25)患者,随机分为治疗组和对照组,每组30例。治疗组采用补肾调肝方(毓麟珠合柴胡舒肝散)每日1剂,早晚分服;对照组选用二甲双胍片(1 000 mg/次),每日2次,早晚随餐口服;两组疗程均为3个月。观察治疗前后空腹血糖(fasting plasma glucose,FPG)、空腹胰岛素(fasting insulin,FINS),稳态胰岛素抵抗指数(homeostasis model assessment-insulin resistance,HOMA-IR)、TC、TG、体重指数(body mass index,BMI)、腰臀比(waist hip ratio,WHR)、黄体生成素(luteinizing hormone,LH)、卵泡雌激素(follicle stimulating hormone,FSH)、LH/FSH以及游离睾酮(free testosterone,T)水平变化。结果与本组治疗前比较,对照组FPG、FINS、LH/FSH及BMI下降(P<0.05,P<0.01),治疗组FPG、TC、LH、LH/FSH、WHR及BMI均下降(P<0.05,P<0.01)。与对照组比较,治疗组WHR、BMI、FINS、LH水平差异有统计学意义(P<0.05)。结论非肥胖型PCOS患者不以全身胰岛素抵抗为主要表现;补肾调肝方通过降低LH、LH/FSH,改善糖脂代谢情况,从而对非肥胖型PCOS起到治疗作用。

Objective To observe the effects of Bushen Tiaogan Recipe （BTR） on glucolipid me- tabolism in patients with polycystic ovary syndrome （PCOS）. Methods Totally 60 non-obese PCOS pa- tients [body mass index （RMI） 〈25] with Shen deficiency Gan-qi stagnation syndrome were randomly assigned to the treatment group and the control group, 30 in each group. Patients in the treatment group took BTR （Yulinzhu Decoction and Chaihu Shugan Powder）, one dose per day, taken once in the morn- ing and once in the evening. Patients in the control group took Metformin Tablet （MT）, 1 000 mg each time, twice per day, taken with meals once in the morning and once in the evening. The treatment course was 3 months for all. Fasting plasma glucose （FPG）, fasting insulin （FINS）, homeostasis model assess- ment-insulin resistance （HOMA-IR）, TC, TG, body mass index （BMI）, waist hip ratio （WHR）, luteinizing hormone （LH）, follicle stimulating hormone （FSH）, LH/FSH, and free testosterone （T） were measured before and after treatment. Results Compared with before treatment in the same group, FPG, FINS, LH! FSH, and BMI decreased in the control group （P 〈0.05, P 〈0.01 ） ; FPG, TC, LH, LH/FSH, WHR, and BMI decreased in the treatment group （P 〈0.05, P 〈0.01 ）. Statistical significance existed in WHR, BMI, FINS, and LH between the control group and the treatment group （P 〈0.05）. Conclusions Non-obese PCOS patients weren＇t characterized by insulin resistance. BTR could improve glucolipid metabolism of non-obese PCOS patients by decreasing LH level and LH/FSH. in this way it played therapeutic roles for non-obese PCOS patients.